恶性疟原虫CSP基因重组蛋白及DNA免疫诱导小鼠体液免疫应答比较

本文利用恶性疟原虫FCC1/HN株环子孢子蛋白 (PfCSP)基因DNA质粒通过不同途径、不同剂量免疫小鼠 ,观察其产生的体液免疫应答反应 ,并将其与相应的重组表达蛋白疫苗进行比较。结果显示 :DNA免疫刺激机体产生抗体反应强度的免疫途径依次为肌肉、静脉和皮下 ;宿主对DNA免疫存在一定的剂量依赖性 ;ELISA和Dot -ELISA检测免疫后 4周和 7周 ,DNA质粒组刺激机体产生抗体的滴度均显著低于相应的重组蛋白组。表明PfCSPDNA疫苗与重组表达蛋白疫苗均可刺激小鼠产生特异性体液免疫应答 ,但前者诱导高滴度的抗体反应需要更长的时间     

日本血吸虫混合DNA疫苗pBK-CMV-Sj26/Sj32诱导小鼠的免疫应答

目的　观察含日本血吸虫候选疫苗分子谷胱甘肽S -转移酶 (Sj2 6 )和天冬酰胺肽链酶 (Sj32 )的真核载体 pBK-CMV -Sj2 6 /Sj32诱导小鼠的免疫应答情况。 方法　将质粒按 5 0 μg/只在 0w ,3w ,5w免疫小鼠股四头肌 ,第一次免疫后取小鼠脾细胞作T淋巴细胞转化实验 ;在 0w、3w和 6w经小鼠尾静脉取血 ,ELISA检测血清中抗体效价及阳性反应率。结果　淋巴细胞转化实验示血吸虫成虫抗原能特异性刺激免疫鼠脾细胞 ;第一次免疫后特异性抗体效价开始升高。抗体最高效价为 1∶2 0 ,3次免疫后有 91.7%小鼠血清呈阳性反应。结论　真核载体 pBK -CMV -Sj2 6 /Sj32可诱导小鼠体液及细胞免疫应答     

日本血吸虫混合DNA疫苗pBK-CMV-Sj26/Sj32诱导小鼠的免疫应答

目的　观察含日本血吸虫候选疫苗分子谷胱甘肽S -转移酶 (Sj2 6 )和天冬酰胺肽链酶 (Sj32 )的真核载体 pBK-CMV -Sj2 6 /Sj32诱导小鼠的免疫应答情况。 方法　将质粒按 5 0 μg/只在 0w ,3w ,5w免疫小鼠股四头肌 ,第一次免疫后取小鼠脾细胞作T淋巴细胞转化实验 ;在 0w、3w和 6w经小鼠尾静脉取血 ,ELISA检测血清中抗体效价及阳性反应率。结果　淋巴细胞转化实验示血吸虫成虫抗原能特异性刺激免疫鼠脾细胞 ;第一次免疫后特异性抗体效价开始升高。抗体最高效价为 1∶2 0 ,3次免疫后有 91.7%小鼠血清呈阳性反应。结论　真核载体 pBK -CMV -Sj2 6 /Sj32可诱导小鼠体液及细胞免疫应答     

恶性疟原虫富组氨酸蛋白2重组蛋白与真核表达质粒免疫特性的比较

目的　探讨以恶性疟原虫富组氨酸蛋白 2 (PfHRP2 )为基础的不同形式的侯选疫苗诱导小鼠免疫应答的特性 ,为包含HRP2的恶性疟红内期疫苗的研制提供实验依据。方法　用重组蛋白TP HRP2及真核表达质粒pcDNA3 1(- ) HRP2免疫BALB c小鼠 ,对抗体应答的动力学及特异性进行分析 ,取脾细胞进行体外增殖实验 ,用免疫血清进行P f.体外生长抑制实验。结果　重组蛋白TP HRP2加福氏佐剂诱导BALB c小鼠产生了高水平的抗体 ,其抗体产生快、持续时间久 ,并具较高的特异性 ,细胞应答被同期激活 ,免疫血清可明显抑制红细胞内发育期疟原虫。重组真核表达质粒pcDNA3 1(- ) HRP2诱导BALB c小鼠产生了较高水平和具有一定特异性的抗体 ,其抗体的产生需要多次免疫和较长时间 ,初始化的脾细胞对抗原再刺激的回忆应答显著 ,但免疫血清对疟原虫的体外生长没有抑制作用。结论　HRP2重组蛋白与真核表达质粒在小鼠具有较为不同的免疫特性 ,HRP2重组蛋白疫苗具有潜在的应用前景     

以HBc颗粒为呈现载体的猪囊虫疫苗的构建及其免疫学研究

目的构建以HBc为载体的带有三个猪囊虫抗原表位(n1,n2,n3)的重组融合表达质粒pET-Δc-3n,表达出融合蛋白并纯化,通过免疫小鼠研究其体液免疫效果。方法用PCR法将三个猪囊虫表位分别插入HBc序列的第78-79位之间以及149位之后,再将该序列克隆入pET28a载体中,构建重组表达质粒,用大肠杆菌BL21作宿主菌表达出融合蛋白,并命名为PCCE,纯化后免疫小鼠,检测小鼠的体液免疫应答。用绦虫卵攻击免疫小鼠,并观察疫苗的保护作用。结果测序结果表明重组质粒构建成功,SDSPAGE显示融合蛋白表达正确,并有多聚体形成现象,ELISA检测到高滴度抗体。小鼠体内绦虫卵攻击试验表明疫苗PCCE的相对保护率为89%。结论以HBc为呈现载体的猪囊虫疫苗被成功表达和纯化,该疫苗能诱导较强的体液免疫反应,免疫小鼠对绦虫卵攻击具有较好的免疫保护作用。提示该疫苗PCCE可能具有预防囊虫病的潜在价值。     

DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc

AIM To develop a safe and effective DNA vaccine for inducing humoral and cellular immunological responses against hepatitis B virus surface antigen (HBsAg). METHODS BALB/c mice were inoculated with NV-HB/s, a recombinant plasmid that had been inserted S gene of hepatitis B virus genome and could express HBsAg in eukaryotes. HBsAg expression was measured by ABC immunohistochemical assay, generation of anti-HBs by ELISA and cytotoxic T lymphocyte (CTL), by MTT method, existence of vaccine DNA by Southern blot hybridization and activation of oncogene C-myc by in situ hybridization.RESULTS With NV-HB/s vaccination by intramuscular injection, anti-HBs was initially positive 2 weeks after inoculation while all mice tested were HBsAg positive in the muscles. The titers and seroconversion rate of anti-HBs were steadily increasing as time went on and were dose-dependent. All the mice inoculated with 100 μg NV-HB/ s were anti-HBs positive one month after inoculation, the titer was 1:1024 or more. The humoral immune response was similar induced by either intramuscular or intradermal injection. CTL activities were much stronger (45.26%) in NV-HB/s DNA immunized mice as compared with those (only 6%) in plasmaderived HBsAg vaccine immunized mice. Two months after inoculation, all muscle samples were positive by Southern-blot hybridization for NV-HB/s DNA detection, but decreased to 25%and all were undetectable by in situ hybridization after 6 months. No oncogene Cmyc activation was found in the muscle of inoculation site. CONCLUSION NV-HB/s could generate humoral and cellular immunological responses against HBsAg that had been safely expressed in situ by NV-HB/s vaccination.     

恶性疟原虫FCC1/HN株CSP抗原基因表达产物在小鼠体内的免疫应答研究

目的： 利用ｐｃＤＮＡ３ 质粒作为载体, 在人宫颈癌细胞（ＨｅＬａ 细胞） 中高效表达恶性疟原虫环子孢子蛋白 （ＣＳＰ）, 观察表达产物诱导ＢＡＬＢ／ｃ小鼠免疫的应答水平。方法： 目的基因ＰｆＣＳＰ在ＨｅＬａ 细胞中表达, 将纯化的表达产物免疫接种小鼠, 通过ＥＬＩＳＡ、Ｗｅｓｔｅｒｎ ｂｌｏｔｔｉｎｇ 分析、Ｔ 淋巴细胞增殖实验、ＮＫ 细胞活性检测和Ｔ淋巴细胞亚群测定, 观察其诱导ＢＡＬＢ／ｃ小鼠产生体液免疫和细胞免疫的应答水平。结果： ＥＬＩＳＡ 检测抗体滴度达１∶６ ４００;Ｗｅｓｔｅｒｎ ｂｌｏｔｔｉｎｇ 结果在３８．３ ｋＤａ 相应位置出现较清晰的显色条带;表达产物能特异刺激小鼠脾淋巴细胞增殖、ＣＤ４＋ 与ＣＤ８＋ 细胞有所增加, 并能提高小鼠ＮＫ细胞活性。结论： 真核表达系统ｐｃＤＮＡ３－Ｐｆ／ＨｅＬａ表达产物能特异刺激小鼠产生体液免疫和细胞免疫的应答, 并提高小鼠ＮＫ细胞活性的作用     

弓形虫pVAX1-SAG2真核表达质粒的构建及其诱导的小鼠免疫应答

目的　构建弓形虫主要速殖子表面抗原 2 (SAG2 )编码基因真核表达质粒pVAX1-SAG2 ,并接种小鼠 ,分析其所诱导的免疫应答。方法　以限制性内切酶EcoRⅠ与KpnⅠ双酶切从重组质粒 pGEM/SAG2中获得SAG2目的基因片段 ,约5 92个bp ,将其插入真核表达载体 pVAX1多克隆位点 ,构建重组质粒 pVAX1-SAG2 ,并转化大肠杆菌JM 10 9,阳性克隆以双酶切与PCR法鉴定。大量提取纯化重组质粒 pVAX1-SAG2 ,5 0 μg肌肉注射小鼠左后腿内侧肌肉 ,3周后加强免疫一次 ;RT-PCR检测SAG2在小鼠肌肉中的转录表达 ,流式细胞仪测定T细胞亚群 ,以速殖子虫体抗原作ELISA测定小鼠血清IgG抗体。结果　真核表达重组质粒 pVAX1-SAG2双酶切鉴定及PCR扩增结果与预期结果相符合。RT -PCR从注射部位肌肉组织总RNA中扩增出SAG2目的基因条带 ;重组质粒 pVAX1-SAG2免疫组CD+ 4 细胞数为 32 .35± 5 .38,显著高于空质粒pVAX1及生理盐水 (NS)二对照组 (P <0 .0 1) ,后二者CD+ 4 细胞数分别为 19.6 5± 4 .2 1与 17.84± 1.5 9;免疫组CD+ 8细胞数为 18.6 7± 2 .37,但与空质粒及NS对照组相比 ,差别不显著 (P >0 .0 5 )。ELISA测定结果显示 pVAX1/SAG2免疫组小鼠血清中出现抗弓形虫特异性IgG抗体。结论　构建成功SAG2真核表达重组质粒 pVAX1-SAG2 ,其能在     

含弓形虫ROP1基因真核表达重组质粒DNA免疫小鼠的研究Ⅲ.免疫鼠肌组织表达产物免疫酶法定位及血清IgG抗体测定

目的　用所构建的弓形虫ｐｃＤＮＡ３－ＲＯＰ１ 真核表达重组质粒,经肌肉注射免疫小鼠,观察它在肌组织中的表达及不同免疫途径所诱导的体液免疫应答。方法　碱裂解法大量制备ｐｃＤＮＡ３－ＲＯＰ１ 质粒,免疫ＢＡＬＢ／ｃ小鼠,每只鼠注射１００ｕｇ,两周后同量加强免疫一次,以ｐｃＤＮＡ３ 空质粒及生理盐水组为对照。于免疫后第５０ 天用间接免疫酶法检测注射局部肌组织重组蛋白的表达;ＥＬＩＳＡ法测定ＩｇＧ抗体滴度。结果　免疫鼠肌组织石蜡切片呈特异性阳性反应;血清ＩｇＧ抗体９０天后测定为阳性;皮下及肌肉不同免疫途径血清均显示阳性结果,无显著性差异。结论　ｐｃＤＮＡ３－ＲＯＰ１质粒ＤＮＡ 免疫小鼠后,肌组织内有重组蛋白表达,并能诱导机体产生ＩｇＧ抗体     

Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses

DNA immunization offers a novel approach to inducing humoral and cellular immunity against infectious pathogens. We examined whether such an approach could be used against cryptosporiodiosis, an intestinal disease caused by the protozoan parasite Cryptosporidium parvum. This infection is a major problem for young ruminants and immunosuppressed individuals in whom cryptosporidiosis causes life-threatening symptoms. The life cycle of C. parvum takes place in the enterocytes of the intestinal epithelium. We therefore focused our attention on a route of immunization that might induce a mucosal immunoglobulin (Ig)A response. Eight-week-old BALB/c mice were immunized intranasally with DNA encoding a 15-kDa C. parvum sporozoite antigen (CP15-DNA) cloned onto the plasmid pcDNA3. CP15-DNA-immunized mice developed specific and longlasting production of anti-CP15 Ig A in intestinal secretions and specific IgG in sera 3 months and 1 year after the first DNA inoculation. CP15-DNA-immunized mice also developed an antigen-specific T lymphocyte proliferative response in both spleen and mesenteric lymph nodes. Control mice that received the pcDNA3 plasmid alone did not develop specific humoral and cellular responses. These results indicate that plasmid DNA may provide a powerful means of eliciting intestinal humoral and cellular responses to C. parvum infections in mammals.     

弓形虫和乙型肝炎病毒混合核酸疫苗的研究Ⅲ.pcDNA3-HBsAg-GRA1免疫小鼠的保护性观察

目的观察重组质粒pcDNA3HBsAgGRA1DNA接种诱导的保护性免疫应答。方法质粒DNA免疫BALB/c小鼠;ELISA法检测GRA1、HBsAg抗体及亚类水平;提取各免疫组小鼠肌肉组织DNA进行PCR检测;弓形虫RH强毒株攻击感染各免疫组小鼠。结果经pcDNA3HBsAgGRA1免疫组小鼠产生抗GRA1和HBsAg抗体,且抗GRA1的抗体水平明显高于GRA1单独和GRA1与HBsAg混合免疫组。弓形虫RH强毒株攻击感染pcDNA3HBsAgGRA1免疫组小鼠,其存活时间明显长于其他各组,结果提示HBsAg可能起免疫佐剂作用。结论将GRA1与HBsAg融合明显增强了GRA1的免疫原性和保护性。     

细粒棘球绦虫Eg95基因疫苗和重组抗原诱导小鼠免疫应答的比较研究

目的观察比较细粒棘球绦虫Eg95重组抗原和基因疫苗诱导小鼠的免疫应答状况。方法实验组和对照组小鼠分别注射Eg95重组抗原(rEg95)、费氏佐剂(FCA)、pcDNA3-Eg95基因疫苗、pcDNA3质粒和生理盐水,收集各组血清用酶联免疫吸附(ELISA法)检测抗体IgG和IgG2a亚类水平;采集脾细胞用四甲基偶氮唑盐试验(MTT法)检测免疫小鼠的脾淋巴细胞增殖反应。结果rEg95免疫组小鼠在第二次免疫后开始检测到抗Eg95抗原的IgG,并随着免疫次数的增多,血清抗体效价升高,在第1次免疫后第10周时,免疫抗体滴度可达到1∶25,600。Eg95基因疫苗免疫的小鼠产生抗体滴度随免疫次数的增加而升高,最高可达1∶3,200,但是低于Eg95重组蛋白免疫小鼠产生的抗体滴度水平。pcDNA3-Eg95免疫组产生IgG2a亚类抗体水平明显高于对照组和rEg95组。在第四次免疫后,进行淋巴细胞转化试验,MTT法检测证实rEg95和pcD-NA3-Eg95免疫的小鼠,其脾细胞均可在体外被特异性刺激增生。结论细粒棘球绦虫Eg95重组抗原和基因疫苗均可诱发小鼠产生特异性免疫应答。     

Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral mmune responses that results in protective immunity in a murine model of hepatitis C virus infection

INTRODUCTION Dendritic cells (DCs) play a pivotal role in the initiation of immune responses and are considered as important targets for effective immunotherapeutic strategies against cancer and infectious diseases[1,2]. DCs acquire antigen in peripheral …     

丙型肝炎病毒核心基因免疫研究

目的研究丙型肝炎病毒（ＨＣＶ）核心（Ｃ）基因免疫用于预防和治疗ＨＣＶ感染的可行性和有效性．方法将ＨＣＶＣ基因片段插入真核表达载体ｐｃＤＮＡ３质粒ＣＭＶ启动子的下游，在证实其可以在小鼠骨髓瘤细胞ＳＰ２／０（Ｈ２ｄ）中表达之后，将重组质粒注射ＢＡＬＢ／ｃ（Ｈ２ｄ）小鼠股四头肌，ＥＬＩＳＡ检测血清中抗体产生水平；３ＨＴｄＲ掺入法测定免疫小鼠淋巴细胞ＨＣＶＣ抗原特异性增殖能力，４ｈ５１Ｃｒ释放法检测免疫小鼠细胞毒Ｔ细胞（ＣＴＬｓ）体外杀伤功能．结果免疫小鼠２０只，初次免疫２ｗｋ后，血清中均出现了ＨＣＶＣ抗体，且增加免疫剂量可提高抗体滴度；淋巴细胞增殖指数为６１０，明显高于对照组（Ｐ＜００１），ＣＴＬｓ体外特异性杀伤率为６３１％，也高于对照组（Ｐ＜００１）．结论ＨＣＶＣ基因免疫不仅可以诱导机体产生特异性的体液免疫，而且产生特异性的细胞免疫，它可能是防治ＨＣＶ的有效方法．     

汉赛巴通体重组外膜蛋白Pap31的研制和抗原性分析

目的克隆并表达汉赛巴通体Pap31外膜蛋白基因,并对其抗原性进行初步分析。方法采用PCR从汉赛巴通体基因组DNA扩增外膜蛋白基因pap31,将目的基因片段插入原核表达质粒pQE30,构建重组质粒pQE30/pap31;将构建的重组质粒转化大肠杆菌M15并诱导目的基因表达,以SDS-PAGE电泳以及免疫印迹法分析表达目的蛋白。结果在SDS-PAGE电泳分析发现pQE30/pap31转化菌高效表达一重组蛋白,经免疫印迹分析发现该蛋白与汉赛巴通体免疫血清发生强烈反应;经间接免疫荧光分析发现该重组蛋白免疫血清能特异识别汉赛巴通体。结论汉赛巴通体外膜蛋白基因pap31在大肠杆菌高效表达,表达的重组Pap31外膜蛋白具有良好的抗原性。     

恶性疟原虫DNA疫苗在小鼠体内组织分布和安全性的初步研究

目的　探讨疟疾DNA疫苗在小鼠体内的组织分布 ,并对其安全性进行观察。方法　将重组质粒pBK -CSP经肌肉途径免疫BALB/c小鼠 ,分别在 4周和 8周后剖杀动物并摘取各种组织 ,抽提全组织DNA进行PCR扩增后经琼脂糖凝胶电泳分析 ,并对DNA疫苗的安全性进行观察。结果　免疫 4周和 8周后 ,仅有DNA疫苗接种位点的肌肉组织检测到CSP基因 ,而 10 0 μg的质粒DNA并未产生明显的毒副作用。 结论　疟疾DNA疫苗接种 4周后 ,质粒DNA仅分布于接种部位 ,并可持续至 8周以上 ,而未发现毒副作用。     

Differential immune response in mice immunized with the A,R or C domain from TcSP protein of Trypanosoma cruzi or with the coding DNAs

In a murine model of experimental Trypanosoma cruzi (H8 strain) infection, we investigated the induction of protective immunity against the domains [amino (A), repeats (R) and carboxyl (C)] of the surface protein (SP), a member of the trans‐sialidase (TS) superfamily. Recombinant proteins and plasmid DNA coding for the respective proteins were used to immunize BALB/c mice, and the humoral response and cytokine levels were analysed. Immunization with the recombinant proteins induced higher levels of anti‐TcSP antibodies than immunization with the corresponding DNAs, and analysis of serum cytokines showed that immunization with both recombinant proteins and naked DNA resulted in a Th1–Th2 mixed T‐cell response. Mice immunized with either recombinant proteins or plasmid DNA were infected with blood trypomastigotes. The recombinant protein‐immunized mice showed a variable reduction in peak parasitemia, and most died by day 60. Only the pBKTcSPR‐immunized mice exhibited a significant reduction in peak parasitemia and survived the lethal challenge. DNA‐based immunization with DNA coding for the repeats domain of TcSP is a good candidate for the development of a vaccine against experimental T. cruzi infection.     

Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs

BACKGROUND: A prophylactic vaccine for hepatitis C virus (HCV) requires generation of strong humoral as well as CD4(+) and CD8(+) T cell responses. METHODS: The immunomodulatory effects of the combination of 2 adjuvants, synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs emulsified with Montanide ISA720 (M-ISA720/CpG), were investigated using the murine model. RESULTS: Administration of recombinant HCV (rHCV) nonstructural (NS) 3 and NS5B proteins plus M-ISA720/CpG (hereafter, "M-ISA720/CpG/rHCV protein") induced high anti-NS3 and anti-NS5B immunoglobulin (Ig) G titers, with the IgG2a isotype being predominant. NS3- and NS5B-specific interferon (IFN)- gamma - and interleukin-2-producing CD4(+) T cell responses, as assessed by enzyme-linked immunospot assay, were significantly more vigorous in mice immunized with M-ISA720/CpG/rHCV protein than in control mice immunized without adjuvant. NS3- and NS5B-specific IFN- gamma -producing CD8(+) T cell percentages, as measured by direct ex vivo intracellular cytokine staining assay, were, respectively, a mean+/-SD of 0.14% +/- 0.04% and 0.15% +/- 0.05% in mice immunized with M-ISA720/CpG/rHCV protein. Furthermore, boosting with recombinant NS3 expression plasmid DNA after priming with M-ISA720/CpG-adjuvanted rNS3 strikingly enhanced both CD4(+) and CD8(+) T cell responses. CONCLUSION: Immunization with M-ISA720/CpG/rHCV protein is capable of inducing potent humoral as well as HCV-specific T helper type 1-biased CD4(+) and CD8(+) T cell responses. A DNA boost after a protein prime--a reversal of the conventional approach--may provide an alternative path to the development of an effective HCV vaccine.     

丙型肝炎病毒核心基因免疫诱生细胞免疫应答研究

目的 研究丙型肝炎病毒（ＨＣＶ）核心（Ｃ）基因免疫在诱生特异性细胞免疫应答中的作用。方法 将包含ＨＣＶ Ｃ基因片段的重组真核表达质粒ｐｃＣＮＡ ＨＣＶ Ｃ,在主宰其可以在小鼠骨髓瘤ＳＰ２／０（Ｈ－２^d）中表达之后,注射ＢＡＬＢ／ｃ小鼠股四头肌。ＥＬＩＳＡ法检测血清中抗体水平;^3Ｈ－ＴｄＲ掺入法测定免疫小鼠脾细胞特异性增殖能力;^51Ｃｒ释放法检测免疫小鼠细胞毒性Ｔ淋巴细胞（ＣＴＬｓ）体外杀伤功能。结     

恶性疟原虫富组氨酸蛋白-2基因诱导的免疫应答研究

[目的 ]探讨编码恶性疟原虫富组氨酸蛋白 2 (HRP Ⅱ )C端基因的真核表达重组质粒诱导小鼠的体液和细胞免疫效果。 [方法 ]将起始码和终止码引入HRP ⅡC端基因片段两端 ,经测序鉴定读框 ,将包含起始码和终止码的HRP Ⅱ基因片段克隆入真核表达质粒pcDNA3 1( )中 ,进行酶切鉴定。用重组真核表达质粒pcDNA3 1( ) /HRP Ⅱ 经肌肉免疫小鼠 3次 ,每次间隔 3wk。第 3次免疫后 2wk ,取小鼠血清和脾细胞 ,分别用ELISA测定HRP Ⅱ抗体水平和用脾细胞增殖实验测定细胞免疫反应。 [结果 ]序列测定结果表明 ,HRP ⅡC端基因片段被准确地引入起始码和终止码 ;酶切鉴定表明包含起始码和终止码的HRP ⅡC端基因片段成功地克隆入pcDNA3 1( ) ,形成pcDNA3 1( ) /HRP Ⅱ 。在pcDNA3 1( ) /HRP Ⅱ 免疫鼠血清中可检测出高水平的HRP Ⅱ抗体 ,用原核表达的HRP Ⅱ蛋白刺激免疫脾细胞 ,可检测出明显的细胞增殖反应。 [结论 ]编码HRP Ⅱ的真核表达重组质粒可诱导小鼠产生明显的体液和细胞免疫反应。其有可能作为恶性疟原虫红内期复合DNA疫苗的候选基因